Using a smartwatch to track how fast people can move may help identify who’s at risk for Parkinson’s disease up to seven years before symptoms become evident and doctors make a diagnosis, a study suggests. Wearing the smartwatch for a week was enough to feed an artificial intelligence (AI)-powered…
The Center for Movement Disorders and Neurorestoration at the University of California (UC) Davis Health Department of Neurology will serve as a Parkinson’s Foundation Center of Excellence starting this month and for at least the next five years. The center joins a Global Care Network that’s grown…
BrainTale raised €4.5 million (about $5 million) to speed further development of software that can decode changes in the brain’s white matter into information that can predict, diagnose, and monitor the progression of diseases such as Parkinson’s. With this round of financing, led by investors Capital Grand…
UB-312, an experimental vaccine by Vaxxinity, appeared safe and well tolerated and was able to produce an immune response against toxic alpha-synuclein protein aggregates in people with early Parkinson’s disease, according to data from a clinical trial. According to the company, UB-312 met the primary objectives of the…
Axial Therapeutics will use a new research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance its experimental therapy for Parkinson’s disease, AX-5006, from ongoing preclinical studies into a first clinical trial in humans. The company is conducting a series of preclinical studies…
People with Parkinson’s disease who are experiencing cognitive decline may show weaker low-frequency brain waves on an electroencephalogram (EEG), a recording of the brain’s electrical activity, according to a recent study. Brain waves recorded at the front part of the brain were linked to measures of cognitive decline and…
A grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will allow Icometrix — a company focused on artificial intelligence (AI) solutions for treating disease — to further advance its work on early biomarkers of Parkinson’s in brain magnetic resonance imaging (MRI) scans. “With this research, we…
Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its oral therapy IkT-148009, announced that its 201 trial program just dosed its first participant. The Phase 2 trial (NCT05424276) is assessing the safety and tolerability of IkT-148009 versus a…
Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication used to treat symptoms during off episodes in Parkinson’s disease, to become available in China. Parkinson’s is a growing problem in China due to the country’s aging population; by…
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…
Get regular updates to your inbox.
